I TUOI DATI
I TUOI ORDINI
N. prodotti: 0
Totale ordine: € 0,00
I TUOI ABBONAMENTI
I TUOI ARTICOLI
Rivista di Pediatria, Neonatologia, Medicina dell’Adolescenza
e Neuropsichiatria Infantile
Indexed/Abstracted in: CAB, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,532
Minerva Pediatrica 2016 Sep 06
Prevention of syncytial respiratory virus infection with palivizumab. Descriptive and comparative analysis after 12 years of use
Eduardo NARBONA-LOPEZ 1, Jose UBEROS 1, Ana CHECA-ROS 1, Rocio RODRIGUEZ-BELMONTE 2, Antonio MUÑOZ-HOYOS 1 ✉
1 Unit of Clinical Paediatrics, San Cecilio University Hospital, Granada, Spain; 2 Paediatric Specialist, St Mary’s Hospital, Imperial College NHS Trust, QEQM Wing, London, UK
BACKGROUND: The use of Palivizumab has been recommended to prevent Syncytial Respiratory Virus infection in vulnerable children.
METHODS: We performed a retrospective study of hospital admissions for bronchiolitis from 2000 to 2012 in the context of a prevention study with Palivizumab in at-risk newborns.
RESULTS: A total of 952 children (59.5% males) were admitted due to bronchiolitis. Admissions occurred in younger children in the SRV+ cases compared to the SRV- cases (p < 0.001). Additionally, 641 children were treated with Palivizumab at our service. Sixty of these children (9.8%) were admitted due to bronchiolitis and SRV was detected in 22 of them (3.4%). Fifty (7.8%) had underlying diseases, 6 (0.9%) presented with a history of perinatal infection and 20 (3.12%) had been part of a multiple birth. The treated children with some additional risk factor presented a greater risk of admission due to bronchiolitis (OR = 1.99, p = 0.045); however, this was not observed for admissions due to SRV (p = 0.945).
CONCLUSIONS: Children treated with Palivizumab showed a lower rate of SRV infection, despite having more risk factors associated with a higher risk of infection or complications.